The global animal CRISPR therapeutics market is projected to grow from USD 2.4 billion in 2026 to USD 9.8 billion by 2031, at a 32.1% CAGR, driven by single-dose cures for genetic diseases and USDA fast-track approvals.

Market Segmentation

1. By Application
   • Monogenic Disorders (45% share):
     • Canine Duchenne muscular dystrophy (DMD) therapy
     • Feline polycystic kidney disease (PKD) cure
   • Oncology (XX%):
     • CAR-T cell editing for canine lymphoma
   • Infectious Disease (XX%):
     • FIV-resistant cats via CCR5 gene knockout
2. By Animal Type
   • Companion Animals (XX% revenue):
     • Dogs (XX%), cats (XX%), horses (10%)
   • Livestock (XX%):
     • PRRS-resistant pigs (commercialized 2025)
3. By Delivery System
   • AAV Vectors (XX%)
   • Lipid Nanoparticles (30%)
   • Electroporation (XX%)

2. Key Growth Drivers

1. Clinical Efficacy Breakthroughs

• Canine DMD Trial:
  • 80% dystrophin restoration at 12 months (UC Davis)
• Feline PKD Cure:
  • Stops cyst growth with single injection (CRISPR Tx)

2. Regulatory Acceleration

• USDA's 2025 Gene Edit Policy:
  • Exempts single-base edits from GMO regulation
• FDA Center of Excellence:
  • 6-month review pathway for veterinary gene therapies

3. Economic Viability

• One-Time Treatment:
  • 15,000 cost vs. 15,000 cost vs. 5,000/year for chronic management
• Breeder Adoption:
  • Champion lines preserve genetics with edited offspring

3. Competitive Landscape

4. Future Outlook (2026-2031)

• 2027: First FDA-approved CRISPR product (canine DMD)
• 2029: Germline editing for inherited conditions
• 2031: 30% of purebred litters genetically optimized